ALRN News and Press, Aileron Therapeutics Inc. From 03/30/20

Aileron Therapeutics (NASDAQ: ALRN ): Q4 GAAP EPS of -$0.26 beats by $0.01 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data suggests reduction in severe anemia and thrombocytopenia; encouraging results led to t...

WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. ...

Aileron Therapeutics, Inc. (ALRN) Q3 2019 Earnings Conference Call November 07, 2019 08:30 AM ET Company Participants Rick Wanstall - Head of Finances Manuel Aivado - President & Chief Executive Officer Vojislav Vukovic - Chief Medical Officer Allen Annis - Head of Research...

Aileron Therapeutics (NASDAQ: ALRN ): Q3 GAAP EPS of -$0.28 misses by $0.03 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification Pre...

WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m. ET on Thursday, November 7, 2019 to ...

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients wit...

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients w...

The first participant has completed the initial cycle of treatment in a 120-subject  Phase 1b/2 clinical trial evaluating Aileron Therapeutics' ( ALRN +5.5% ) ALRN-6924 as a myelopreservation agent in patients with p52 mutation-positive small cell lung cancer (SCLC) treated with the ...